CompletedPhase 2NCT02273596

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Studying Wilson disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alexion Pharmaceuticals, Inc.
Principal Investigator
Eugene Swenson, MD, PhD
Alexion Pharmaceuticals, Inc.
Intervention
ALXN1840(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
2014 – 2018

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02273596 on ClinicalTrials.gov

Other trials for Wilson disease

Additional recruiting or active studies for the same condition.

See all trials for Wilson disease →

← Back to all trials